Literature DB >> 16249358

Nimotuzumab: evidence of clinical benefit without rash.

David G P Allan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16249358     DOI： 10.1634/theoncologist.10-9-760

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  23 in total

1.  Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.

Authors:  Yaima Tundidor; Claudia Patricia García-Hernández; Amaury Pupo; Yanelys Cabrera Infante; Gertrudis Rojas
Journal:  MAbs       Date:  2014-04-23       Impact factor: 5.857

2.  Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Authors:  Dirk Strumberg; Beate Schultheis; M E Scheulen; R A Hilger; J Krauss; N Marschner; F Lordick; F Bach; D Reuter; L Edler; K Mross
Journal:  Invest New Drugs       Date:  2010-12-21       Impact factor: 3.850

3.  A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma.

Authors:  Yang Ling; Jia Chen; Min Tao; Xiaoyuan Chu; Xizhi Zhang
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

4.  Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.

Authors:  Yun Yang; Qingcheng Guo; Mao Xia; Yantao Li; Xiaoyun Peng; Tao Liu; Xin Tong; Jin Xu; Huaizu Guo; Weizhu Qian; Sheng Hou; Jianxin Dai; Hao Wang; Rong Liu; Yajun Guo
Journal:  MAbs       Date:  2015       Impact factor: 5.857

5.  Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab.

Authors:  Usha Patel; Sadhana Kannan; Swapnil U Rane; Neha Mittal; Poonam Gera; Asawari Patil; Subhakankha Manna; Vishwayani Shejwal; Vanita Noronha; Amit Joshi; Vijay M Patil; Kumar Prabhash; Manoj B Mahimkar
Journal:  Br J Cancer       Date:  2022-02-09       Impact factor: 9.075

6.  Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Authors:  Maria Teresa Solomon; Nederlay Miranda; Eugenia Jorrín; Ivonne Chon; Jorge Juan Marinello; José Alert; Patricia Lorenzo-Luaces; Tania Crombet
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

Review 7.  Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Authors:  Melarkode S Ramakrishnan; Anand Eswaraiah; Tania Crombet; Patricia Piedra; Giselle Saurez; Harish Iyer; A S Arvind
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

8.  Effects of an epidermal growth factor receptor-based cancer vaccine on wound healing and inflammation processes in murine experimental models.

Authors:  Dasha Fuentes; Lewis Chacón; Angel Casacó; Nuris Ledón; Nidia Fernández; Arianna Iglesias; Diana R Hernández; Belinda Sánchez; Rolando Pérez
Journal:  Int Wound J       Date:  2012-09-04       Impact factor: 3.315

Review 9.  Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.

Authors:  Dietrich A Ruess; Kivanc Görgülü; Sonja M Wörmann; Hana Algül
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 4.271

Review 10.  Control of advanced cancer: the road to chronicity.

Authors:  Agustin Lage; Tania Crombet
Journal:  Int J Environ Res Public Health       Date:  2011-03-01       Impact factor: 3.390
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.